Skip to content Skip to sidebar Skip to footer

🔬 Spotlight on a Pharmaceutical Pioneer
We are thrilled to share the fantastic news of our client’s I-140 Approval after an RFE, completed through Premium Processing! This is not just an approval; it’s a testament to dedication and brilliance.

👩‍🔬 Meet the Trailblazer
Our client, an aspiring Ph.D. scholar in Pharmaceutical Sciences, is reshaping the world of drug development. With a rich tapestry of roles – from manufacturing intern to research assistant, and clinical pharmacy expertise – her journey is nothing short of inspiring. Co-author of several pivotal publications, she’s a vanguard in enhancing drug efficacy and delivery. Balancing scientific rigor with heart, she’s also deeply involved in community service. Her groundbreaking research? Transforming oral drug delivery for hemochromatosis in thalassemia and sickle cell patients.

⌛ A Timeline of Tenacity
– RFE Issued: October 10, 2023

Join us in celebrating this monumental achievement! 🎉 Here’s to breaking barriers and setting new benchmarks in the pharmaceutical world!

Processing Type Premium Processing
Priority Date October 2, 2023
I-140 Approved January 4, 2024
Immigration Status F-1 OPT
Degrees  Ph.D. candidate in Pharmaceutical Sciences, M.S. in Pharmaceutical Sciences, Bachelor of Pharmacy
Proposed Endeavour Pioneering drug delivery therapy for sickle cell and Alzheimer’s disease.
Work Experience Manufacturing intern, Research Assistant, and Clinical pharmacy expert
Publications  Co-author of several pivotal publications
Achievement Her profile boasted
– Membership in 3 Professional Societies, attendance at 3 major conferences
– 6 initial Recommendations, plus 2 more post-RFE
– Impressive tally of 9 Publications/Research Experiences
– Cited in 4 other works
– Heartfelt involvement in 2 Volunteer Activities
– Recognition with 5 Certifications, 1 Award, 4 Scholarships
– Substantial evidence of relevant professional experience

Leave a comment